Blood test study for N/OFQ in AML
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at a substance in the blood called N/OFQ in people with acute myeloid leukemia (AML). Researchers want to see if its level is related to the disease, which could help with future care. It is a blood test study, not a treatment trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adult acute myeloid leukemia (AML) but not the promyelocytic subtype.
- Your white blood cell count is 25,000 or less (25×10⁹/L).
- You have not received any leukemia treatment in the past 6 months.
- You are not allergic to any of the drugs used in this study.
- You do not have a mental illness or cognitive impairment that could interfere with the study.
- You do not have an active infection, severe heart/liver/kidney problems, or another type of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, FD-001, for people with certain blood cancers (like leukemia, lymphoma, or myeloma) that have come back or stopped responding to standard treatments. The goal is to see if the drug is safe and how well it might work.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial studies whether a combination medicine (ATO plus ATRA) is safe and works better in people with a specific type of AML (acute myeloid leukemia) caused by an NPM1 mutation. You would join only after your leukemia has reached remission, meaning the active leukemia has cleared after initial treatment.
This trial tests an oral medication (NTQ2494) for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if the drug is safe and effective.
This study looks at certain proteins in the blood (called FLT3 ligand and IL6) of people being treated for blood cancers like AML, MDS, or CMML. The goal is to understand how these proteins change during non-intensive chemotherapy, which may help doctors better personalize treatment.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.